Does the media prefer AXSM or TRLV?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Trulieve Cannabis. MarketBeat recorded 20 mentions for Axsome Therapeutics and 12 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.30 beat Axsome Therapeutics' score of 0.06 indicating that Trulieve Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Trulieve Cannabis 0 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, TRLV or LNTH?

Lantheus has higher revenue and earnings than Trulieve Cannabis. Lantheus is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.18B 1.80 -$116.38M $0.11 100.41 Lantheus $1.56B 4.25 $233.56M $4.06 25.03

Does the media prefer TRLV or LNTH?

In the previous week, Trulieve Cannabis had 1 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Trulieve Cannabis and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.67 beat Trulieve Cannabis' score of 0.30 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRLV or AMRX?

In the previous week, Trulieve Cannabis had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for Trulieve Cannabis and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.86 beat Trulieve Cannabis' score of 0.30 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRLV or BLTE?

In the previous week, Trulieve Cannabis had 7 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Trulieve Cannabis and 5 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.95 beat Trulieve Cannabis' score of 0.30 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MANE or TRLV?

In the previous week, Veradermics had 7 more articles in the media than Trulieve Cannabis. MarketBeat recorded 19 mentions for Veradermics and 12 mentions for Trulieve Cannabis. Veradermics' average media sentiment score of 0.75 beat Trulieve Cannabis' score of 0.30 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Trulieve Cannabis (TRLV) Competitors

$11.36 +0.27 (+2.39%)

As of 09:59 AM Eastern

Compare

TRLV vs. AXSM, LNTH, AMRX, BLTE, and MANE

Should you buy Trulieve Cannabis stock or one of its competitors? Trulieve Cannabis's main competitors and comparable companies include Axsome Therapeutics (AXSM), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Belite Bio (BLTE), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trulieve Cannabis compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Axsome Therapeutics had 8 more articles in the media than Trulieve Cannabis. MarketBeat recorded 20 mentions for Axsome Therapeutics and 12 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.30 beat Axsome Therapeutics' score of 0.06 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trulieve Cannabis	0 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	11.61	-$183.17M	-$3.06	N/A
Trulieve Cannabis	$1.18B	1.80	-$116.38M	$0.11	100.41

Axsome Therapeutics has a net margin of -18.18% compared to Trulieve Cannabis' net margin of -41.22%. Trulieve Cannabis' return on equity of -0.34% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-18.18%	-198.73%	-22.03%
Trulieve Cannabis	-41.22%	-0.34%	-0.14%

Axsome Therapeutics currently has a consensus target price of $267.58, suggesting a potential upside of 89.81%. Trulieve Cannabis has a consensus target price of $15.00, suggesting a potential upside of 35.81%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Axsome Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Axsome Therapeutics beats Trulieve Cannabis on 9 of the 15 factors compared between the two stocks.

How does Trulieve Cannabis compare to Lantheus?

Trulieve Cannabis (NYSE:TRLV) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

In the previous week, Trulieve Cannabis had 1 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Trulieve Cannabis and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.67 beat Trulieve Cannabis' score of 0.30 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Trulieve Cannabis. Lantheus is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.18B	1.80	-$116.38M	$0.11	100.41
Lantheus	$1.56B	4.25	$233.56M	$4.06	25.03

99.1% of Lantheus shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Trulieve Cannabis currently has a consensus target price of $15.00, suggesting a potential upside of 35.81%. Lantheus has a consensus target price of $107.44, suggesting a potential upside of 5.73%. Given Trulieve Cannabis' higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21

Lantheus has a net margin of 17.28% compared to Trulieve Cannabis' net margin of -41.22%. Lantheus' return on equity of 29.26% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.22%	-0.34%	-0.14%
Lantheus	17.28%	29.26%	15.40%

Summary

Lantheus beats Trulieve Cannabis on 11 of the 14 factors compared between the two stocks.

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Trulieve Cannabis (NYSE:TRLV) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.18B	1.80	-$116.38M	$0.11	100.41
Amneal Pharmaceuticals	$3.20B	2.14	$72.06M	$0.42	50.90

Amneal Pharmaceuticals has a net margin of 4.17% compared to Trulieve Cannabis' net margin of -41.22%. Amneal Pharmaceuticals' return on equity of 283.50% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.22%	-0.34%	-0.14%
Amneal Pharmaceuticals	4.17%	283.50%	7.79%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Trulieve Cannabis had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for Trulieve Cannabis and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.86 beat Trulieve Cannabis' score of 0.30 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trulieve Cannabis currently has a consensus price target of $15.00, suggesting a potential upside of 35.81%. Amneal Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 7.58%. Given Trulieve Cannabis' higher probable upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Amneal Pharmaceuticals beats Trulieve Cannabis on 12 of the 14 factors compared between the two stocks.

How does Trulieve Cannabis compare to Belite Bio?

Trulieve Cannabis (NYSE:TRLV) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

0.5% of Belite Bio shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Trulieve Cannabis' net margin of -41.22%. Trulieve Cannabis' return on equity of -0.34% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.22%	-0.34%	-0.14%
Belite Bio	N/A	-11.84%	-11.62%

In the previous week, Trulieve Cannabis had 7 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Trulieve Cannabis and 5 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.95 beat Trulieve Cannabis' score of 0.30 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trulieve Cannabis currently has a consensus target price of $15.00, suggesting a potential upside of 35.81%. Belite Bio has a consensus target price of $227.40, suggesting a potential upside of 45.28%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio has lower revenue, but higher earnings than Trulieve Cannabis. Belite Bio is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.18B	1.80	-$116.38M	$0.11	100.41
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

Belite Bio beats Trulieve Cannabis on 8 of the 13 factors compared between the two stocks.

How does Trulieve Cannabis compare to Veradermics?

Veradermics (NYSE:MANE) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Veradermics has a net margin of 0.00% compared to Trulieve Cannabis' net margin of -41.22%. Veradermics' return on equity of 0.00% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Trulieve Cannabis	-41.22%	-0.34%	-0.14%

Veradermics has higher earnings, but lower revenue than Trulieve Cannabis. Veradermics is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Trulieve Cannabis	$1.18B	1.80	-$116.38M	$0.11	100.41

Veradermics currently has a consensus price target of $174.57, suggesting a potential upside of 17.80%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 35.81%. Given Trulieve Cannabis' higher possible upside, analysts plainly believe Trulieve Cannabis is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Veradermics had 7 more articles in the media than Trulieve Cannabis. MarketBeat recorded 19 mentions for Veradermics and 12 mentions for Trulieve Cannabis. Veradermics' average media sentiment score of 0.75 beat Trulieve Cannabis' score of 0.30 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veradermics beats Trulieve Cannabis on 8 of the 11 factors compared between the two stocks.

Get Trulieve Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRLV vs. The Competition

Export

Metric	Trulieve Cannabis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.19B	$13.79B	$7.90B	$23.46B
Dividend Yield	N/A	2.58%	2.47%	3.73%
P/E Ratio	56.85	30.13	35.34	28.39
Price / Sales	2.02	6.59	8.37	3.38
Price / Cash	N/A	15.75	22.22	15.97
Price / Book	2.83	4.94	4.40	3.73
Net Income	-$116.38M	$2.87B	$3.50B	$1.08B
7 Day Performance	-1.68%	-0.55%	-1.48%	-1.12%
1 Month Performance	6.75%	-5.87%	-4.53%	0.67%
1 Year Performance	N/A	-6.51%	1.39%	6.09%

Trulieve Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRLV Trulieve Cannabis	3.6754 of 5 stars	$11.36 +2.4%	$15.00 +32.1%	N/A	$2.19B	$1.08B	56.85	5,000	News Coverage Earnings Report Short Interest Decrease
AXSM Axsome Therapeutics	3.5278 of 5 stars	$139.61 +2.6%	$269.89 +93.3%	+2.3%	$7.12B	$638.50M	N/A	925	Trending News Analyst Revision
LNTH Lantheus	2.8869 of 5 stars	$100.80 +0.5%	$107.44 +6.6%	+100.5%	$6.55B	$1.54B	20.14	1,193	Earnings Report
AMRX Amneal Pharmaceuticals	3.8571 of 5 stars	$20.21 -1.1%	$22.63 +11.9%	+86.2%	$6.53B	$3.02B	23.77	8,500	Analyst Downgrade
BLTE Belite Bio	3.515 of 5 stars	$152.17 -1.0%	$227.40 +49.4%	+33.4%	$6.19B	N/A	N/A	41	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TRLV) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trulieve Cannabis (TRLV) Competitors

TRLV vs. AXSM, LNTH, AMRX, BLTE, and MANE

How does Trulieve Cannabis compare to Axsome Therapeutics?

Summary

How does Trulieve Cannabis compare to Lantheus?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Summary

How does Trulieve Cannabis compare to Belite Bio?

Summary

How does Trulieve Cannabis compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trulieve Cannabis (TRLV) Competitors

TRLV vs. AXSM, LNTH, AMRX, BLTE, and MANE

How does Trulieve Cannabis compare to Axsome Therapeutics?

Does the media prefer AXSM or TRLV?

Which has preferable valuation and earnings, AXSM or TRLV?

Is AXSM or TRLV more profitable?

Do analysts recommend AXSM or TRLV?

Do institutionals and insiders have more ownership in AXSM or TRLV?

Summary

How does Trulieve Cannabis compare to Lantheus?

Does the media prefer TRLV or LNTH?

Which has preferable earnings and valuation, TRLV or LNTH?

Do insiders & institutionals have more ownership in TRLV or LNTH?

Do analysts recommend TRLV or LNTH?

Is TRLV or LNTH more profitable?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Which has preferable valuation & earnings, TRLV or AMRX?

Is TRLV or AMRX more profitable?

Do insiders and institutionals have more ownership in TRLV or AMRX?

Does the media refer more to TRLV or AMRX?

Do analysts rate TRLV or AMRX?

Summary

How does Trulieve Cannabis compare to Belite Bio?

Do institutionals and insiders have more ownership in TRLV or BLTE?

Is TRLV or BLTE more profitable?

Does the media prefer TRLV or BLTE?

Do analysts prefer TRLV or BLTE?

Which has stronger earnings & valuation, TRLV or BLTE?

Summary

How does Trulieve Cannabis compare to Veradermics?

Is MANE or TRLV more profitable?

Which has stronger earnings and valuation, MANE or TRLV?

Do analysts recommend MANE or TRLV?

Does the media prefer MANE or TRLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools